ESR1 and breast carcinoma: However, breast cancer cells inevitably develop resistance to endocrine therapy through the emergence of activating mutations of the ESR1 gene from which ERα is expressed or increased signaling by multiple different receptor tyrosine kinases and c-Myc (12–15).